A pdf version of the programme with abstracts can be found here.
09:30-10:00 Registration and welcome
10:00-10:15 : Introductory talks by Hervé Raoul (deputy director of ANRS-MIE), Rodolphe Thiébaut (Bordeaux U.) and
Eric Quéméneur (director of the France Vaccins programme) - France Vaccins, collaborative R&D as a catalyst for vaccine development
10:15-10:45 : Yves Lévy (Vaccine Research Institute, Henri Mondor de Créteil Hospital) - Do modelling tools add value to systems vaccinology? Why, How, When?
10:45-11:40 : Session on pre-clinical vaccine development
- Véronique Godot (Paris-Est Créteil University) - Broad and durable antibody responses following CD40.Pan.CoV vaccination: Biological insights leading to modelling approaches
- Roger Le Grand (CEA)
- Mélanie Prague (INRIA Bordeaux) - Mathematical modeling of humoral response and mechanistic correlates of protection against SARS-CoV-2 variants in pre-clinical studies
Short break
11:50-12:30 : Session on clinical vaccine development
- Laura Richert (Bordeaux University) - Optimizing early-phase clinical development of vaccines
- Liem Binh Luong Nguyen (AP-HP, Paris Cité University) - Measuring vaccine efficacy : how models can help
12:30-13:10 : Session on viral evolution and impacts on vaccines
- Jean-Sébastien Casalegno (UCBL, Hospices Civils de Lyon) - Escalating immune pressure against RSV fusion protein: Are vaccines and monoclonals on the razor's edge?
- Noémie Lefrancq (ETH Zürich) - Monitoring the impact of vaccine implementation on population-level pathogen fitness dynamics
Lunch
14:15-15:10 : Session on decision support for vaccine strategies
- Andrea Lasserre (Haute Autorité de Santé) - How vaccines are evaluated by the French National Authority for Health and role of models in this evaluation
- Paolo Bosetti (Institut Pasteur) - Modeling the impact of meningococcal vaccination in France over the next 40 years
- David Smith (University of Oxford) - Modelling to guide vaccine rollout in low- and middle-income countries: the example of Lassa fever
15:10-16:05 : Session on efficacy assessment in populations
- Mahmoud Zureik (EPI-PHARE, UVSQ, AP-HP) - Epidemiological surveillance of Covid-19 vaccines : Efficacy/Safety
- Naïm Ouldali (AP-HP, Paris Cité University) - Assessing effectiveness of new vaccines through population-based cohorts
- Lulla Opatowski (UVSQ, INSERM, Pasteur Institute) - Challenges in modelling vaccine impact for multi-strain pathogens
Coffea break
16:30-17:25 : Session on vaccine hesitancy and social issues around vaccines
- Alessia Melegaro (Bocconi University) - Integrating human behaviour into epidemiological models: Insights from vaccination decision research
- Patrick Peretti-Watel (INSERM, Aix-Marseille University) - Using various data and models to study vaccination behaviors. Some examples from a work in progress
- Jocelyn Raude (EHESP) - What modelers should know about vaccine acceptance: instrumental and axiological factors in vaccination decision-making
17:25-17:30 : Conclusion
